Changchun Genescience Pharmaceutical announced NMPA clearance to initiate clinical trials of Gensci‑136, a dual APRIL/BAFF antagonist for immunoglobulin A nephropathy (IgAN). The NMPA clearance authorizes first‑in‑human dosing of the injectable biologic, marking a regulatory milestone for a mechanism that targets B‑cell survival signals implicated in IgAN pathophysiology. For biotechs focused on kidney immunology, the move signals China’s ongoing emphasis on advancing novel biologics into clinical testing and could prompt competitive development updates from peers pursuing BAFF/APRIL biology.